EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network

Tse-Yu Chen, Ya-Lian Deng, I-Chieh Chen, Ching-Heng Lin, Jun-Fu Lin, Yi-Ming Chen, Hsu-Tung Lee, Hui-Chih Hung

Bone · 2026

DOI: 10.1016/j.bone.2025.117678 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Bone, 2026. Verfasst von Tse-Yu Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; Department of Neurosurgery, Neurological Institute, Taich…. Hauptthemen laut MEDLINE: Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Chung Hsing University, Taichung Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Medication-related osteonecrosis of the jaw (MRONJ) was first reported in cancer patients receiving high-dose intravenous bisphosphonates and later linked to other anti-resorptive agents such as denosumab and romosozumab. However, large-scale real-world data on MRONJ risk following these therapies remain limited. This study focuses on the widely used parenteral anti-resorptive agents-ibandronate, denosumab, and zoledronic acid-chosen for their clinical popularity, cost-effectiveness, and convenient dosing. We aimed to assess the risk of MRONJ associated with each agent using real-world data from a global healthcare network. METHODS: This retrospective cohort study was conducted using the TriNetX network. To clarify the causal relationship, cohorts were created to include patients treated with only one anti-resorptive medication. Propensity score matching was applied to adjust for known risk factors associated with MRONJ. Additionally, subgroup analyses were performed for cancer and non-cancer patient populations. RESULTS: Propensity score matching yielded balanced cohorts (n = 36,983 each) for comparing MRONJ risk. Among matched patients, 106 denosumab users and 41 zoledronic acid users developed MRONJ (HR: 0.378; 95 % CI: 0.264-0.543). No case occurred in the ibandronate group (n = 11,405), which showed substantially lower risk compared to zoledronic acid and denosumab. The incidence of inflammatory condition of jaws share similar trends compared to those of MRONJ among the three groups. In cancer patients, MRONJ risk was 0.294 % with denosumab and 0.525 % with zoledronic acid. Non-cancer patients had much lower risk. CONCLUSIONS: This study used real-world data from the TriNetX platform to evaluate the risk of MRONJ associated with various anti-osteoporosis medications, excluding combination therapies for clarity. Our findings indicate that among the commonly used parenteral anti-resorptive agents, denosumab has been associated with the highest risk of MRONJ, followed by zoledronic acid, with ibandronate showing the lowest risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisBisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsHumansRetrospective StudiesFemaleMaleAgedMiddle AgedDenosumabDiphosphonatesZoledronic AcidRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

Anti-resorptive drugsDenosumabIbandronateMRONJ (medication-related osteonecrosis of jaws)OsteoporosisZoledronic acid

Substanzen

Bone Density Conservation AgentsDenosumabDiphosphonatesZoledronic Acid

Autor:innen und Institutionen

  • Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan; Rong Hsing Translatio…
  • Department of Nursing, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Public Health, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Department of Industrial Engin…
  • Division of Translational Medicine, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veter…
  • Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.

Förderung

  • National Chung Hsing University
  • Taichung Veterans General Hospital

Zitieren

APA

Chen, T. Y., Deng, Y. L., Chen, I. C., Lin, C. H., Lin, J. F., Chen, Y. M., Lee, H. T., & Hung, H. C. (2026). Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network. Bone. https://doi.org/10.1016/j.bone.2025.117678

Vancouver

Chen TY, Deng YL, Chen IC, Lin CH, Lin JF, Chen YM, et al. Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network. Bone. 2026. doi:10.1016/j.bone.2025.117678

BibTeX
@article{Chen2026,
  author = {Chen, Tse-Yu and Deng, Ya-Lian and Chen, I-Chieh and Lin, Ching-Heng and Lin, Jun-Fu and Chen, Yi-Ming and Lee, Hsu-Tung and Hung, Hui-Chih},
  title = {Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network},
  journal = {Bone},
  year = {2026},
  doi = {10.1016/j.bone.2025.117678}
}
Kostenlos starten →